Home

If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk

overview

SMi is proud to present the 21st Annual Pain Therapeutics Virtual Conference on 10th and 11th May 2021.

The global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Chronic pain is a major health care problem that affects some 30%-50% of the world population and almost 20% of Europeans suffer from chronic or intermittent pain; the latter results in suffering and disability for patients and increasing economic loss for society.

The 21st Annual Conference will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers. Join Europe's leading Pain Therapeutics Conference which will analyse the latest developments in the field of pain drug development and learn how to industry is working to overcome the challenges of opioid base treatment.
 

Learn about how new advances in big data are being applied within drug development to aid precision medicine
Discuss recent findings on the effects of Botulinum neurotoxin for pain management and how these molecules can become useful therapeutic agents
Explore the opioid crisis and the recent advances in finding alternative compounds to opioids
Discover what the industry has learnt from COVID-19 and the impact on the pain therapeutics industry

Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Departments, Principal Research Scientists, Clinical Lead, Clinical Operations in the following fields:
• Pain and Migraine
• Pain Innovation R&D
• Neuroscience
• CNS
• Neuropathic Pain
• Analgesic clinical development
• Anesthesia and Pain Management
• CNS clinical trials
• Translational science
• Drug development
• Discovery Medicine
• Exploratory development
• Clinical and pharmaceutical operations
• Medical Affairs

Analgesic Innovation; Centrexion Therapeutics Corp; Collegium Pharmaceuticals; Eli Lilly And Company; Gruenenthal LTD; Grunenthal Group; GSK; Independent; INSERM; Janssen Pharmaceutica N.V.; Metys Pharmaceuticals Ltd; MSD; Mundipharma Research Limited; National Institute of Neurological Disorders and Stroke National Institutes of Health; National Institutes Of Health; Pain Alliance Europe (PAE); Pharmaleads; Pierre Fabre Research Institute; Teva Pharmaceuticals; Transpharmation Ltd; UCL; UCL Institute of Ophthalmology; University of Edinburgh; USAISR; Venesco, LLC; Versus Arthritis;

Conference programme

All timings are in British Summer Time (GMT+1)

8:30 Registration & Coffee

10:00 Chairman's Opening Remarks

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

Naheed Mirza

Naheed Mirza, Early Development Pain & CNS Specialist ,
View Bio

10:10 Update: Demonstration of significant pain relief in subjects with painful osteoarthritis of the knee with a novel anti NGF, anti-TNFa bispecific fusion protein

10:40 Therapeutic novelties signifying a paradigm shift in migraine prevention

Dalma Sugar

Dalma Sugar, Medical Affairs Director, Teva Pharmaceuticals

• What are the novel drug targets?
• What are the major progresses in migraine therapies?
• Exploring the targeted pathways and understanding the role of neuropeptides
• The potential for future studies on identification of biomarkers that can predict treatment response
 

11:10 Morning Break and Virtual Exhibit Hall Open

11:40 Botulinum neurotoxin for pain management

Mikhail Kalinichev

Mikhail Kalinichev, Director, in vivo Neurology, Ipsen
View Bio

• Highlighting recent findings on the effects of BoNTs in animal pain models
• Investigating the effects of BoNT/A on neuropathic pain
• Can these extremely poisonous molecules can become useful therapeutic agents in a number of expanding applications in human medicine?
• Progress of BoNT/A for treatment of pain in various types of headache and migraine conditions
 

12:10 Novel Targets in Pain: Sigma 1

Naheed Mirza

Naheed Mirza, Early Development Pain & CNS Specialist ,
View Bio

• Introduction to Sigma1 proteins
• Emerging Preclinical and Clinical data on novel Sigma1 molecules
• Opportunities and Challenges in prosecuting Sigma1
 

12:40 The Potential Role of the Type 3 Adenosine Receptor Modulators

Joseph V. Pergolizzi

Joseph V. Pergolizzi, Chief R&D Officer , Neumentum
View Bio

• Examine the adenosine receptors system
• Define the potential Moa related to analgesia
• Explore a novel aRM3 nTM-006 existing data

13:10 Networking Break and Virtual Exhibit Hall Open

14:10 The NIH HEAL initiative: efforts to enhance pain management through therapy development programs

Smriti Iyengar

Smriti Iyengar, Director, PSPP, Program Director, NINDS, NINDS/NIH
View Bio

• Accelerate the discovery and development of non-opioid, non-addictive therapeutics through preclinical and clinical therapy development programs in NINDS
• Rigor and reproducibility as guiding principles
• Multiple modalities including small molecules, biologics, devices and natural products are within scope
• Opportunities for academic and industry asset owners worldwide
 

14:40 Expanding advantages and insights with new porcine models

Sigal Meilin

Sigal Meilin, Chief Scientific Officer, MD Biosciences

Expanding advantages and insights with new porcine models

  • Employing porcine models in the study of pain. Why pigs?
  • Differences and applications of Minipigs and domestic pigs
  • Sex differences in withdrawal response and outcome
  • IENF Differences in male and female, non-operated pigs
  • Future development plans
  • 15:20 Spotlight Session: Exploring the expansion of pain research at the National Institutes of Health

    David A. Thomas

    David A. Thomas, Senior Advisor to the Director, National Institutes of Health
    View Bio

    • Focussing on the need to consider race as a variable in pain research and therapeutic development
    • Discussing the bias against those experiencing pain in pain research and pain treatment
    • Defining racial and ethnic disparities in pain management
    • Highlighting the need for greater pain education to overcome such bias

     

    15:50 Panel: Seeking funding for pain clinical research trials

    • Which organisations in Europe can provide funding for research and development of drugs for pain relief?
    • What recommendations can the larger pharmaceutical companies give the small biotech companies in terms of seeking funding for clinical trials?
    • Where is funding most needed?
    • Strategies to generate more funding into pain research to eliminate the issue of underfunding
     

    Michael Scherz

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
    View Bio

    Smriti Iyengar

    Smriti Iyengar, Director, PSPP, Program Director, NINDS, NINDS/NIH
    View Bio

    David A. Thomas

    David A. Thomas, Senior Advisor to the Director, National Institutes of Health
    View Bio

    Tina Doshi

    Tina Doshi, Assistant Professor of Pain Medicine, Johns Hopkins University
    View Bio

    16:25 Afternoon Break and Virtual Exhibit Hall Open

    16:55 Diversity matters: The importance of sex and gender in pain research

    Tina Doshi

    Tina Doshi, Assistant Professor of Pain Medicine, Johns Hopkins University
    View Bio

    • Identify sex and gender differences in pain, including biomarkers, molecular targets, clinical and experimental models of pain
    • Recognize gender gaps in pain patient treatment and among pain clinicians
    • Understand the benefits of diversity among pain researchers and clinicians as important steps for developing personalized pain care
    • Discuss strategies for improving diversity in pain medicine
     

    17:25 Biomarker use in Pain Clinical Studies: Where have we been and where should we go?

    Richard Malamut

    Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals
    View Bio

    • Identifying the role of biomarkers to evaluate target engagement of new drugs and predict the analgesic efficacy of new drugs
    • Discussing progress, challenges and gaps to facilitate the development of biomarkers
    • Highlighting the importance of biomarker discovery and its contribution to early stage studies on pain
    • Reflecting on ideas to stimulate research and technology development in this area of high unmet medical need
     

    17:55 Chairs’ Closing Remarks and Close of Day One

    Naheed Mirza

    Naheed Mirza, Early Development Pain & CNS Specialist ,
    View Bio

    Michael Scherz

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd

    8:30 Registration & Coffee

    10:00 Chairman's Opening Remarks

    Michael Scherz

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
    View Bio

    Naheed Mirza

    Naheed Mirza, Early Development Pain & CNS Specialist ,
    View Bio

    10:10 Phase 2 clinical trial results of racemic dimiracetam for the treatment of antiretroviral treatment-related neuropathic pain: lessons for the Phase 2 clinical trial of MP-101, a non-racemic mixture of the dimiracetam enantiomers

    Michael Scherz

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd

    • A failed Phase 2 trial by dimiracetam's previous Sponsor
    • A post-hoc PK-based analysis; a second post-hoc PK-based analysis
    • A safety assessment
    • A few lessons we've applied to our plans for MP-101, a patented non-racemic mixture of the dimiracetam enantiomers
     

    10:40 Development of a novel non-drowsy skeletal muscle relaxant: What is the current unmet medical need?

    Randall Kaye

    Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals
    View Bio

    • Discussing the mechanisms of Tolperisone and its applications in pain relief
    • How can Tolperisone help treat acute back spasms without causing drowsiness?
    • Exploring Tolperisone as the first muscle relaxant for the treatment of symptoms associated with acute and painful muscle spasms of the back
    • Presenting Neurana’s work in developing an ultra-pure formulation of Tolperisone, not available in other countries that has a lower degradant yield and meets ICH guidance
     

    11:10 Morning Break and Virtual Exhibit Hall Open

    11:40 Deep Dive: Exploring Novaremed’s work in developing NRD.E1, an innovative therapy for diabetic neuropathic pain

    Sara Mangialaio

    Sara Mangialaio, CMO, Head of R&D, Novaremed
    View Bio

    • Discussing Novaremed’s lead drug, NRD.E1 as a non-opioid small molecule for the treatment of neuropathic pain
    • Analysing the results from a proof of concept study
    • Understanding the potential of NRD.E1 in addressing a major unmet medical need in diabetic neuropathic pain
     

    12:10 AP-325 as a novel, non-opioid treatment for neuropathic pain

    Guido Koopmans

    Guido Koopmans, CSO, Algiax Pharmaceuticals Gmbh
    View Bio

    • Introduction to AP-325
    • Discussing emerging preclinical and phase I data on novel AP-325
    • How can AP-325 aid towards the treatment of chronic neuropathic pain without causing serious side-effects on the central nervous system?
    • Exploring AP-325 as an important approach in the fight against the opiate crisis
     

    12:40 Panel: Rethinking pain clinical trials during the COVID-19 pandemic

    • Overview of current pain clinical trials taking place
    • How has COVID-19 changed the experience in which we approach data verification, data analysation and data collection?
    • How are patients managed differently in clinical trials during this period?
    • How has COVID-19 presented an opportunity to reform the way we conduct clinical trials moving forward?
    • How have we adapted to change and remained flexible during the era of COVID-19?
     

    Achim Kless

    Achim Kless, Pain Genetics Lead, Eli Lilly & Company
    View Bio

    Guido Koopmans

    Guido Koopmans, CSO, Algiax Pharmaceuticals Gmbh
    View Bio

    Randall Kaye

    Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals
    View Bio

    Joseph V. Pergolizzi

    Joseph V. Pergolizzi, Chief R&D Officer , Neumentum
    View Bio

    13:15 Networking Break and Virtual Exhibit Hall Open

    14:15 CLE-400 - a novel non-opioid topical treatment for painful peripheral diabetic neuropathy

    Orna Goren

    Orna Goren, Products Cluster leader, Clexio Biosciences

    14:45 Exploring genetics in common pain diseases

    Luda Diatchenko

    Luda Diatchenko, Professor, McGill University
    View Bio

    • Common genetic variants as markers for analgesic responses
    • Common genetic variants in pain target discovery
    • Use of common genetic variants diseases for reconstructing pathophysiology of chronic pain
     

    15:15 Covalent and non-covalent TRPA1 agonists exert distinct ligand-binding and pain mechanisms

    Jun Chen

    Jun Chen, Senior Scientist, Genentech
    View Bio

    • Reporting the discovery of a non-covalent agonist, GNE551 and determining a cryo-EM structure of the TRPA1-GNE551 complex
    • Understanding how GNE551 activates TRPA1 into a distinct conducting state without desensitization and induces persistent pain
    • Exploring how GNE551-evoked pain is relatively insensitive to antagonist treatment
    • Demonstrating the biased agonism of TRPA1, a finding that has important implications for the discovery of effective drugs tailored to different disease
     

    15:45 Afternoon Break and Virtual Exhibit Hall Open

    16:15 Exploring pain genetics in rare diseases

    Achim Kless

    Achim Kless, Pain Genetics Lead, Eli Lilly & Company
    View Bio

    • From GWAS results to novel pain targets
    • Exploring rare variants in pain target discovery
    • Pain phenotypes across traits
    • Future of drug development for rare diseases
     

    16:45 Long-lasting Analgesia via Repression of NaV1.7 using CRISPR-dCas9 and Zinc-Finger Proteins

    Ana Moreno

    Ana Moreno, CEO, Navega Therapeutics
    View Bio

    • DNA-level repression of key genes responsible for pain transmission holds great therapeutic potential
    • Discussing future applications of epigenome regulation to treat pain using CRISPR-dCas9 and Zinc-Finger proteins.
    • Demonstrate the efficacy of this approach to prevent and treat neuropathic preclinical pain models
    • Demonstrate preliminary safety results of this approach.
     

    17:15 An overview of volatile anaesthetics and their applications in pain therapeutics

    Heather Giles

    Heather Giles, CEO and Chief Scientific Officer, Vapogenix
    View Bio

    • Discussing how volatile anaesthetics can alleviate pain
    • Exploring how volatile anaesthetics (VAs) can treat inflammatory pain associated with musculoskeletal diseases such as rheumatoid arthritis, gout and osteoarthritis
    • To what extent can volatile anaesthetics be considered as an effective alternative to opioids?
    • What is the future of volatile anaesthetics within pain therapeutics?
     

    17:45 Chairs’ Closing Remarks and Close of Day Two

    Naheed Mirza

    Naheed Mirza, Early Development Pain & CNS Specialist ,
    View Bio

    Michael Scherz

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
    View Bio

    +

    Sponsors

    Exhibitors

    Official Media Partner

    Supporters

    VENUE

    Online Virtual Event

    Online Virtual Event , Online Virtual Event , United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Speaker Interview with Sigal Meilin, MD Biosciences

    Download

    Speaker Interview with Guido Koopmans, Algiax Pharmaceuticals Gmbh

    Download

    Speaker Interview with Achim Kless, Eli Lilly & Company

    Download

    Speaker Interview with Randall Kaye, Neurana Pharmaceuticals

    Download

    Co-Chairs Invite Letter to Pain Therapeutics Conference

    Download

    Pain Therapeutics 2021 Brochure

    Download

    Pain Therapeutics 2021 Long Programme

    Download

    Pain Therapeutics 2021 Short Programme

    Download

    2021 Chair and Speaker Biographies

    Download

    Past Attendees - Pain Therapeutics

    Download

    Past Speaker Presentation - Vifor Pharma

    Download

    Past Speaker Presentation - University College London

    Download

    Past Speaker Presentation - Teva Pharmaceuticals

    Download

    Past Speaker Presentation - Pain Alliance Europe

    Download

    Past Speaker Presentation - Pierre Fabre Research Institute

    Download

    Past Speaker Presentation - Collegium

    Download

    Sponsors


    MD Biosciences

    Sponsors
    https://www.mdbneuro.com

    MD Biosciences Neuro is a preclinical and translational contract research organization (CRO) offering services for drug development in the field of neurology and pain research. We understand that finding a trust-worthy preclinical partner is a top priority for drug developers and believe that you should have confidence in the partner you choose. That's why we are dedicated to providing each client valued expertise and advice, experience for flawless execution, and flexibility to meet the needs of rapidly changing requirements.

    With a presence in the innovation hubs of Cambridge, Massachusetts and with state of the art laboratories in Israel, our team is dedicated to building collaborative programs and creating lasting partnerships in the biotechnology community.


    Exhibitors


    Transpharmation

    Exhibitors
    http://www. transpharmation.co.uk

    Transpharmation is a preclinical CRO led by scientists. Building on the founders' international reputation and CNS drug discovery expertise, Transpharmation's global client base benefit from decades of experience in preclinical translational neuroscience, including pain & inflammation, EEG, cognition, epilepsy, neurodegeneration and anxiety/mood disorders, together with a biomarker platform.

    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.


    Pain News

    Official Media Partner
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.


    The British Journal of Pain

    Official Media Partner
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.

    Media Partners


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Genetic Engineering News

    Supporters
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Hospital & Healthcare Management

    Supporters
    https://www.hhmglobal.com/media-pack



    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out